According to a new study in Stroke, women who were sexually abused during childhood may be more likely to have higher intima media thickness, suggesting that stressors in early life may have an impact on cardiovascular disease (CVD) later in life.
According to a new study in Stroke, women who were sexually abused during childhood may be more likely to have higher intima media thickness, suggesting that stressors in early life may have an impact on cardiovascular disease (CVD) later in life.
The findings are based on data from 1402 participants in The Study of Women’s Health Across the Nation (SWAN), a longitudinal cohort study of women going through menopause led by researchers from the University of Pittsburgh. To assess the association between childhood sexual abuse and risk of adult CVD, the women-who were white, black, Hispanic, or Chinese-underwent measurements of childhood and adult physical and sexual abuse, blood draw, physical measures; and had a carotid artery ultrasound at SWAN visit 12.
Linear and multinomial logistic regression models were used to test the association between abuse and intima media thickness and plaque while controlling for age, site, race/ethnicity, financial strain, education, body mass index, lipids, blood pressure, measures of insulin resistance, smoking, alcohol use, physical activity, and medication use.
When controlling for typical CVD risk factors and other confounders, a history of childhood sexual abuse was associated with higher intima media thickness (β=0.022; SE=0.010; P<0.05; adjusted mean childhood sexual abuse: 0.800 mm versus no childhood sexual abuse: 0.782 mm).
Investigators concluded that a history of childhood sexual abuse was positively associated with higher intima media thickness, even after controlling for typical CVD risk factors. They believe that their findings highlight the potential impact of early-life stressors on later cardiovascular health.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Exploring menstrual health: Insights from the Avon longitudinal study
December 5th 2023Unveiling a comprehensive analysis of menstrual cycle characteristics in mothers and daughters, this article delves into the diverse features, potential risk factors, and the importance of understanding these nuances for effective menstrual health management.
Read More
Integrating pharmacists into PPHTN management for enhanced blood pressure control
December 4th 2023A study reveals that involving pharmacists in the care of postpartum women at risk of persistently elevated blood pressure, as presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition, can provide an effective and feasible solution to managing hypertensive disorders, reducing postpartum readmission risks, and improving overall health care access.
Read More